商品名: Keytruda/可瑞达价格 通用名:Pembrolizumab Injection/帕博利珠单抗注射液 制药商:MSD/默沙东制药 规格: 4ml:100mg瓶/盒 索引:帕博利珠单抗(K药)
【英文名称】KEYTRUDA Injection(Pembrolizumab(Genetical Recombination)) 【中文名称】派姆单抗重组注射剂 派姆单抗剂量和给药方法 ⑴每3周给予2 mg/kg作为历时30分钟静脉输注。 ⑵ 静脉输注前重建和稀释。 剂型和规格 ⑴ 为注射:50mg,为重建在一次性使用小瓶中冰冻干燥粉。 ⑵ 注射用: 100mg/4mL(25 mg/mL)溶...
一.K药,新的适应症也已经提交上市申请: 1.2018年7月25日,默沙东PD-1单抗Keytruda(帕博利珠单抗)-Pembrolizumab的中国上市申请(JXSS1800002)正式获得国家药品监督管理局(NMPA)批准,成为继百时美施贵宝Opdivo之后第2个正式在中国上市的PD-1/PD-L1单抗类药物。 第一个国内获批的适应症是:晚期恶性黑色素瘤。 黑色素瘤...
About KEYTRUDA® (pembrolizumab) injection, 100 mg KEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cells....
About KEYTRUDA® (pembrolizumab) injection, 100 mg KEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. KEYTRUDA ...
KEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S. Approval: 2014 - RECENT MAJOR CHANGES - Indications and Usage (1.2) 10/2015 Dosage and Administration (2.1, 2.3) 10/2015 Dosage and Administration (2.4) 01/2015 ...
KEYTRUDA® (pembrolizumab) for injection, for intravenous use KEYTRUDA® (pembrolizumab) injection, for intravenous use Initial U.S. Approval: 2014 --- RECENT MAJOR CHANGES --- Indications and Usage (1.2) 10/2015 Dosage and Administration (2.1, 2.3) 10/2015 Dosage and Administration (2.4) ...
Active ingredient:pembrolizumab Inactive ingredients:L-histidine, polysorbate 80, sucrose, and water for injection Who makes Keytruda? Keytruda is manufactured by Merck & Co. (known as MSD outside the United States and Canada), and their global headquarters are located in Rahway, New Jersey, USA...
Pembrolizumab is available as Keytruda as 100 mg/4 mL (25 mg/mL) single-dose vials for intravenous infusion. Monotherapy: Adult individuals with unresectable or metastatic melanoma: 200 mg every 3 weeks or 400 mg every 6 weeks until disease progression or unacceptable toxicity ...
About KEYTRUDA®(pembrolizumab) injection, 100 mg KEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. KEYTRUDA ...